These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 7687816

  • 1. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
    Nichols WW, Nicolini FA, Khan S, Saldeen TG, Mehta JL.
    Am Heart J; 1993 Aug; 126(2):285-92. PubMed ID: 7687816
    [Abstract] [Full Text] [Related]

  • 2. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
    Nicolini FA, Mehta JL, Nichols WW, Saldeen TG, Grant M.
    Circulation; 1990 Mar; 81(3):1115-22. PubMed ID: 1689620
    [Abstract] [Full Text] [Related]

  • 3. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 4. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 5. Combined thrombolytic effects of tissue-plasminogen activator and a fibrinogen-degradation product peptide 6A or iloprost.
    Nichols WW, Nicolini FA, Saldeen TG, Mehta JL.
    J Cardiovasc Pharmacol; 1991 Aug; 18(2):231-6. PubMed ID: 1717784
    [Abstract] [Full Text] [Related]

  • 6. Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Khan S, Mehta JL.
    Am Heart J; 1992 Aug; 124(2):280-8. PubMed ID: 1322029
    [Abstract] [Full Text] [Related]

  • 7. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 8. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ.
    Pharmacology; 1991 Dec; 42(6):340-8. PubMed ID: 1946598
    [Abstract] [Full Text] [Related]

  • 9. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
    Mehta JL, Nichols WW, Saldeen TG, Chandna VK, Nicolini FA, Lawson DL, ter Riet MF.
    J Cardiovasc Pharmacol; 1990 Jul; 16(1):112-20. PubMed ID: 1696653
    [Abstract] [Full Text] [Related]

  • 10. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ.
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator.
    Shebuski RJ, Sitko GR, Claremon DA, Baldwin JJ, Remy DC, Stern AM.
    Blood; 1990 Apr 01; 75(7):1455-9. PubMed ID: 1969293
    [Abstract] [Full Text] [Related]

  • 12. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
    Mehta JL, Chen L, Nichols WW, Johannesen M, Bregengård C, Hedner U, Saldeen TG.
    J Am Coll Cardiol; 1995 Mar 01; 25(3):753-60. PubMed ID: 7860925
    [Abstract] [Full Text] [Related]

  • 13. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D.
    Circulation; 1991 Mar 01; 83(3):1038-47. PubMed ID: 1900221
    [Abstract] [Full Text] [Related]

  • 14. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP.
    Circulation; 1992 Feb 01; 85(2):805-15. PubMed ID: 1735171
    [Abstract] [Full Text] [Related]

  • 15. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs.
    Yao SK, Ober JC, Garfinkel LI, Hagay Y, Ezov N, Ferguson JJ, Anderson HV, Panet A, Gorecki M, Buja LM.
    Circulation; 1994 Jun 01; 89(6):2822-8. PubMed ID: 8205697
    [Abstract] [Full Text] [Related]

  • 16. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
    Yasuda T, Gold HK, Fallon JT, Leinbach RC, Garabedian HD, Guerrero JL, Collen D.
    J Am Coll Cardiol; 1989 May 01; 13(6):1409-14. PubMed ID: 2495318
    [Abstract] [Full Text] [Related]

  • 17. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.
    Nicolini FA, Lee P, Malycky JL, Lefkovits J, Kottke-Marchant K, Plow EF, Topol EJ.
    Blood Coagul Fibrinolysis; 1996 Jan 01; 7(1):39-48. PubMed ID: 8845461
    [Abstract] [Full Text] [Related]

  • 18. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec 01; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 19. Increased production of thromboxane A2 by coronary arteries after thrombolysis.
    Saldeen TG, Saldeen P, Nichols WW, Lawson DL, Nicolini FA, Mehta JL.
    Am Heart J; 1993 Feb 01; 125(2 Pt 1):277-84. PubMed ID: 8427117
    [Abstract] [Full Text] [Related]

  • 20. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.
    Nicolini FA, Nichols WW, Mehta JL, Saldeen TG, Schofield R, Ross M, Player DW, Pohl GB, Mattsson C.
    J Am Coll Cardiol; 1992 Jul 01; 20(1):228-35. PubMed ID: 1607530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.